Purple Biotech Ltd.
Develops cancer therapies to overcome tumor immune evasion and drug resistance.
PPBT | TA
Overview
Corporate Details
- ISIN(s):
- IL0007650166
- LEI:
- Country:
- Israel
- Address:
- Oppenheimer 4, 7670104 Rehovot
- Website:
- https://purple-biotech.com/
- Sector:
- Manufacturing
Description
Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-02 01:18 |
Immediate Report of Meeting to be held on June 15, 2023,proxy
|
English | 141.4 KB | ||
| 2023-05-02 01:13 |
Annual General Meeting of Shareholders to be held on June 15, 2023
|
English | 1.3 MB | ||
| 2023-05-02 01:13 |
Annual General Meeting of Shareholders to be held on June 15, 2023
|
English | 36.7 KB | ||
| 2023-04-27 02:10 |
6K:Purple Biotech Debuts Scientific Advisory Board
|
English | 174.7 KB | ||
| 2023-04-27 02:10 |
6K:Purple Biotech Debuts Scientific Advisory Board
|
English | 36.3 KB | ||
| 2023-04-19 17:25 |
6K:Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sens…
|
English | 181.3 KB | ||
| 2023-04-19 17:25 |
6K:Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sens…
|
English | 36.6 KB | ||
| 2023-03-26 00:46 |
6K:Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
|
English | 169.5 KB | ||
| 2023-03-26 00:46 |
6K:Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
|
English | 36.4 KB | ||
| 2023-03-23 16:35 |
FORM F-3 REGISTRATION STATEMENT
|
English | 953.0 KB | ||
| 2023-03-23 16:35 |
FORM F-3 REGISTRATION STATEMENT
|
English | 35.8 KB | ||
| 2023-03-16 14:11 |
6K:Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
|
English | 173.7 KB | ||
| 2023-03-16 14:11 |
6K:Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
|
English | 36.4 KB | ||
| 2023-03-04 22:41 |
FORM 20F FOR 2022
|
English | 1.6 MB | ||
| 2023-03-04 22:41 |
FORM 20F FOR 2022
|
English | 36.6 KB |
Automate Your Workflow. Get a real-time feed of all Purple Biotech Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Purple Biotech Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Purple Biotech Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
